Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529479 | 0.83 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1 | |
| SCHEMBL12584607 | 0.78 | HTR2C (0.46) | HTR2CL3MBTL1NUDT1 | |
| SCHEMBL5477688 | 0.77 | NUDT1 (0.55) | HTR2CL3MBTL1KEAP1NUDT1ADORA1 | |
| SCHEMBL103894 | 0.76 | HTR2C (0.53) | HTR2CL3MBTL1NUDT1ADORA1ADORA2A | |
| SCHEMBL5408532 | 0.75 | NUDT1 (0.52) | L3MBTL1KEAP1NUDT1ADORA2A | |
| SCHEMBL18263959 | 0.74 | HTR2C (0.40) | HTR2CL3MBTL1KEAP1ADORA1ADORA2A | |
| SCHEMBL19616550 | 0.74 | HTR2C (0.43) | HTR2CL3MBTL1 | |
| SCHEMBL30528376 | 0.74 | HTR2C (0.40) | HTR2CL3MBTL1 | |
| SCHEMBL19865160 | 0.73 | L3MBTL1 (0.53) | HTR2CL3MBTL1NUDT1ADORA2A | |
| SCHEMBL24386932 | 0.73 | HTR2C (0.50) | HTR2CL3MBTL1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | HTR2C 1216/4885L3MBTL1 4405/4885KEAP1 577/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | HTR2C 1284/4885L3MBTL1 4401/4885KEAP1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.